Bimatoprost/timolol fixed combination: A 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension

Journal of Glaucoma

Volumn 17, Issue 3, 2008, Pages 211-216

  Brandt, James D ^a   Cantor, Louis B ^a   Katz, L Jay ^a   Batoosingh, Amy L ^a   Chou, Connie ^a   Bossowska, Izabella ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bimatoprost; Fixed combination; Glaucoma; Intraocular pressure; Timolol

Indexed keywords

BIMATOPROST; BIMATOPROST PLUS TIMOLOL; TIMOLOL;

ADULT; AGED; ARTICLE; BURNING SENSATION; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY EYE; EYE PIGMENTATION; EYELASH; EYELASH GROWTH; FEMALE; FOREIGN BODY SENSATION; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; KERATITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR PRURITUS; PARALLEL DESIGN; PHOTOPHOBIA; PIGMENT DISORDER; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GLAUCOMA, ANGLE-CLOSURE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 42149083759     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e3181507313     Document Type: Article

References (16)

1. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
2. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.
3. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
4. European Glaucoma Society. Terminology and guidelines for glaucoma. 2003. Report.
5. Chrai SS, Makoid MC, Eriksen SP, et al. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci. 1974;63:333-338.
6. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112:863-868.
7. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure. Arch Ophthalmol. 1978;96:2045-2048.
8. Yablonski ME, Zimmerman TJ, Waltman SR, et al. A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics. Exp Eye Res. 1978;27:135-142.
9. Brubaker RF, Schoff EO, Nau CB, et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 2001;131:19-24.
10. Cantor LB. An update on bimatoprost in glaucoma therapy. Expert Opin Pharmacother. 2002;3:1753-1762.
11. Hommer A, Ganfort Investigators Group I. A double masked, randomized, parallel, comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17:53-62.
12. Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120:1286-1293.
13. Arai K, Wood JP, Osborne NN. Beta-adrenergic receptor agonists and antagonists counteract LPS-induced neuronal death in retinal cultures by different mechanisms. Brain Res. 2003;985:176-186.
14. Chen J, Dinh T, Woodward DF, et al. Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy. Cardiovasc Drug Rev. 2005;23:231-246.
15. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs. monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006;124:1230-1238.
16. Leal BC, Medeiros FA, Medeiros FW, et al. Conjunctival hyperemia associated with bimatoprost use: a histopathologic study. Am J Ophthalmol. 2004;138:310-313.